Lamivudine
Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.
Clinical data | |
---|---|
Trade names | Epivir, Epivir-HBV, Zeffix, others |
Other names | (−)-L-2′,3′-dideoxy-3′-thiacytidine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a696011 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 86% |
Protein binding | Less than 36% |
Elimination half-life | 5 to 7 hours |
Excretion | Kidney (circa 70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.132.250 |
Chemical and physical data | |
Formula | C8H11N3O3S |
Molar mass | 229.25 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
Common side effects include nausea, diarrhea, headaches, feeling tired, and cough. Serious side effects include liver disease, lactic acidosis, and worsening hepatitis B among those already infected. It is safe for people over three months of age and can be used during pregnancy. The medication can be taken with or without food. Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase.
Lamivudine was patented in 1995 and approved for use in the United States in 1995. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.